389 related articles for article (PubMed ID: 18466054)
1. Alpha-synuclein and Parkinson's disease: a proteomic view.
Fasano M; Lopiano L
Expert Rev Proteomics; 2008 Apr; 5(2):239-48. PubMed ID: 18466054
[TBL] [Abstract][Full Text] [Related]
2. The proteomic approach in Parkinson's disease.
Fasano M; Bergamasco B; Lopiano L
Proteomics Clin Appl; 2007 Nov; 1(11):1428-35. PubMed ID: 21136640
[TBL] [Abstract][Full Text] [Related]
3. Controlling the mass action of alpha-synuclein in Parkinson's disease.
Kim C; Lee SJ
J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice--a model of familial Parkinson's disease.
Poon HF; Frasier M; Shreve N; Calabrese V; Wolozin B; Butterfield DA
Neurobiol Dis; 2005 Apr; 18(3):492-8. PubMed ID: 15755676
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
Lee VM; Trojanowski JQ
Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
[TBL] [Abstract][Full Text] [Related]
6. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?
Chu Y; Kordower JH
Neurobiol Dis; 2007 Jan; 25(1):134-49. PubMed ID: 17055279
[TBL] [Abstract][Full Text] [Related]
7. α-synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson's disease.
Chu Y; Mickiewicz AL; Kordower JH
Neurobiol Dis; 2011 Jan; 41(1):71-82. PubMed ID: 20816781
[TBL] [Abstract][Full Text] [Related]
8. Molecular pathogenesis of Parkinson disease.
Eriksen JL; Wszolek Z; Petrucelli L
Arch Neurol; 2005 Mar; 62(3):353-7. PubMed ID: 15767499
[TBL] [Abstract][Full Text] [Related]
9. Parkinson's disease genetic mutations increase cell susceptibility to stress: mutant alpha-synuclein enhances H2O2- and Sin-1-induced cell death.
Jiang H; Wu YC; Nakamura M; Liang Y; Tanaka Y; Holmes S; Dawson VL; Dawson TM; Ross CA; Smith WW
Neurobiol Aging; 2007 Nov; 28(11):1709-17. PubMed ID: 16978743
[TBL] [Abstract][Full Text] [Related]
10. Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease?
Maguire-Zeiss KA; Short DW; Federoff HJ
Brain Res Mol Brain Res; 2005 Mar; 134(1):18-23. PubMed ID: 15790526
[TBL] [Abstract][Full Text] [Related]
11. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra.
Galvin JE
Acta Neuropathol; 2006 Aug; 112(2):115-26. PubMed ID: 16791599
[TBL] [Abstract][Full Text] [Related]
12. alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease.
Sidhu A; Wersinger C; Vernier P
FEBS Lett; 2004 May; 565(1-3):1-5. PubMed ID: 15135042
[TBL] [Abstract][Full Text] [Related]
13. Proteomic analysis of dopamine and α-synuclein interplay in a cellular model of Parkinson's disease pathogenesis.
Alberio T; Bossi AM; Milli A; Parma E; Gariboldi MB; Tosi G; Lopiano L; Fasano M
FEBS J; 2010 Dec; 277(23):4909-19. PubMed ID: 20977677
[TBL] [Abstract][Full Text] [Related]
14. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
[TBL] [Abstract][Full Text] [Related]
15. Synucleins and their relationship to Parkinson's disease.
von Bohlen Und Halbach O
Cell Tissue Res; 2004 Oct; 318(1):163-74. PubMed ID: 15503152
[TBL] [Abstract][Full Text] [Related]
16. Rescuing defective vesicular trafficking protects against alpha-synuclein toxicity in cellular and animal models of Parkinson's disease.
Lashuel HA; Hirling H
ACS Chem Biol; 2006 Aug; 1(7):420-4. PubMed ID: 17168518
[TBL] [Abstract][Full Text] [Related]
17. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.
Chu Y; Dodiya H; Aebischer P; Olanow CW; Kordower JH
Neurobiol Dis; 2009 Sep; 35(3):385-98. PubMed ID: 19505575
[TBL] [Abstract][Full Text] [Related]
18. Genetic contributions to Parkinson's disease.
Huang Y; Cheung L; Rowe D; Halliday G
Brain Res Brain Res Rev; 2004 Aug; 46(1):44-70. PubMed ID: 15297154
[TBL] [Abstract][Full Text] [Related]
19. Ubiquitin-proteasome system dysfunction in Parkinson's disease: current evidence and controversies.
Lim KL
Expert Rev Proteomics; 2007 Dec; 4(6):769-81. PubMed ID: 18067415
[TBL] [Abstract][Full Text] [Related]
20. Lifetime proteomic profiling of an A30P alpha-synuclein Drosophila model of Parkinson's disease.
Xun Z; Sowell RA; Kaufman TC; Clemmer DE
J Proteome Res; 2007 Sep; 6(9):3729-38. PubMed ID: 17683129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]